Using dual energy CT to differentiate lung adenocarcinoma invasiveness

Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Using Extracellular Volume Measured in Delay Phase

This study is testing if a special type of CT scan can help doctors tell the difference between early lung cancer and precancerous growths to make better treatment decisions for patients.

Quick facts

• Study type: Observational
• Enrollment: 2000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Tang-Du Hospital (other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Xi'an, Shaanxi)
• Trial ID: NCT06441357 on ClinicalTrials.gov

What this trial studies

This observational study aims to determine if the extracellular volume (ECV) fraction measured by dual energy computed tomography (DECT) can effectively distinguish between precancerous lesions and early-stage lung adenocarcinomas. The research focuses on understanding how changes in the tumor microenvironment, particularly the extracellular matrix, correlate with the invasiveness of lung adenocarcinoma. By analyzing the ECV fraction during the delay phase of imaging, the study seeks to provide insights that could inform surgical decision-making for patients diagnosed with lung adenocarcinoma.

Who should consider this trial

Good fit: Ideal candidates include patients over 18 years old with pathologically confirmed lung adenocarcinoma and pulmonary nodules measuring 3 cm or less.

Not a fit: Patients with a history of other malignancies or those who have undergone prior anti-tumor therapies may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the accuracy of surgical decision-making for patients with lung adenocarcinoma.

How similar studies have performed: Previous studies have shown that ECV fraction can effectively differentiate between benign and malignant lung lesions, indicating potential success for this approach.

Eligibility criteria

Inclusion Criteria:

* patients older than 18 years old with pulmonary nodules (diameter≤3 cm).
* pathologically confirmed as lung adenocarcinoma.
* without history of other malignancies.
* accurate hematocrit within 1 week before contrast enhanced dual energy CT examination.

Exclusion Criteria:

* with a history of allergy to iodine contrast agents and other reasons who are unable to complete the examination.
* without histopathology of invasion stage, such as AAH, AIS, MIA and IAC.
* history of chemotherapy, radiotherapy, or other anti-tumor therapy before contrast enhanced dual energy CT.
* poor image quality.
* contrast enhanced dual energy CT scans ≥ 4 weeks before surgery.

Where this trial is running

Xi'an, Shaanxi

• Tangdu Hospital — Xi'an, Shaanxi, China (RECRUITING)

Study contacts

• Study coordinator: Cui Guangbin, Professor

Conditions: Adenocarcinoma of Lung, ECV, invasion, lung adenocarcinoma, DECT